Benefit of Spectral Information in Patients Suspected for Lung Cancer

Status Recruiting

Clinical Trial Summary

Purpose The aim of the study is to investigate the utilization of photon counting CT (PCCT) and the spectral information provided to determine the impact of spectral information on follow-up examinations. As secondary aims we will compare conventional CT, CT + 18Flouro-deoxy-glucose (18F-FDG) positron emission tomography (PET) and PCCT + 18F-FDG PET for the tumor-node-metastasis (TNM) staging of lung cancer patients. PCCT with and without spectral information to assess the need for additional work-up,TNM classification, and sensitivity/specificity for malignant lesions. Patients will be randomized for reading with or without spectral information available within a clinical setting. The clinical readings are performed as a structured reports of all significant findings. Including both malignant and benign findings. Furthermore, in case additional follow-up/work-up is needed based on the guidelines on incidental findings by the American College of Radiology (ACR), this will be reported as well. If lesions suspicious of pulmonary malignancy is present, a provisional TNM classification is provided based on the scan findings. After 3 months, the patient record is reviewed where additional examinations that can be attributed to the PCCT scan are recorded. The financial impact is calculated by a health economist based on the findings. PET/CT, conventional CT and PCCT combined with PET will be assessed retrospectively for comparison. Endpoints are number of supplementary examinations and cost savings. Sensitivity and specificity for any malignant finding. The T, N and M stages are assessed separately as diagnostic measures by the McNemar's test with a reference standard from the Danish Lung cancer register. The number of malignant lesions will be determined by reviewing the patient records incl. pathology assessment if available 12 months after inclusion of the last patient.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06440616
Study type	Interventional
Source	Copenhagen University Hospital at Herlev
Contact	Michael B Andersen, PhD
Phone	38 68 38 68
Email	michael.brun.andersen@regionh.dk
Status	Recruiting
Phase	N/A
Start date	May 24, 2024
Completion date	June 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05890872` - Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer	N/A
Recruiting	`NCT05974475` - MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
Recruiting	`NCT06079970` - Confocal Laser Endomicroscopy VERification	N/A
Recruiting	`NCT04973293` - Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer	N/A
Recruiting	`NCT04778826` - Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy	N/A
Suspended	`NCT04036721` - Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis	Phase 4
Completed	`NCT03352245` - Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer	N/A
Completed	`NCT03834116` - Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies	N/A
Completed	`NCT03824977` - Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
Terminated	`NCT02985203` - Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT05241873` - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Completed	`NCT05404022` - Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years	N/A
Not yet recruiting	`NCT05414188` - Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy	N/A
Recruiting	`NCT03525782` - Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC	Phase 1/Phase 2
Completed	`NCT04059887` - Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]	Phase 4
Terminated	`NCT05013554` - Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.